PARP inhibitor

Biotech

Roche pays Repare $125M to join Big Pharma peers in cancer race

Roche is joining AstraZeneca, Bayer, Merck KGaA and more in a synthetic lethality race, paying $125 million upfront for an ATR inhibitor.
Nick Paul Taylor Jun 2, 2022 8:27am

AstraZeneca re-ups ties with Chinese cancer test maker AmoyDx

Apr 18, 2022 10:42am

Ribon raises $65M to take PARP7 inhibitor deeper into the clinic

Jul 14, 2021 8:20am

Combating BRCA-mutated tumors via a new pathway

Jun 17, 2021 11:00am

Valo to go public via Khosla-backed SPAC, gaining $500M-plus

Jun 10, 2021 4:11am

AACR: Zentalis' WEE1 inhibitor shows promise in phase 1

Apr 10, 2021 1:30pm